^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IPH5201
i
Other names: IPH5201, IPH52, anti-huCD39 mAb
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AstraZeneca, Innate
Drug class:
CD39 inhibitor
Related drugs:
10ms
A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE) (ESMO 2023)
Assessment of exploratory biomarkers is also planned. A Safety Review Committee will conduct evaluations on an ongoing basis and two interim analyses will be performed.
Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker
|
ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
CD73 expression
|
Imfinzi (durvalumab) • IPH5201
11ms
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
P2, N=70, Recruiting, Innate Pharma | Initiation date: Feb 2023 --> Jun 2023
Trial initiation date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
1year
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
P2, N=70, Recruiting, Innate Pharma
New P2 trial
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
over1year
Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale (ESMO-IO 2022)
Targeting the Ado pathway has recently been reported to improve Durvalumab (D) efficacy in early-stage NSCLC patients, through the use of Oleclumab, an anti-CD73 mAb...Finally, in vivo, in a mouse tumor model engrafted in huCD39KI mice, moIPH5201 improved the anti-tumor efficacy of gemcitabine and anti-PD-L1 combination. Conclusions IPH5201 was shown to block CD39 enzymatic activity, to lower Ado and increase ATP levels in the TME and finally to improve anti-tumor efficacy in preclinical models. Altogether, the expression profile of CD39 in early stage NSCLC and preclinical combination data support the clinical evaluation of IPH5201 in combination with D and CT in early stage NSCLC patients.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
PD-L1 expression • CD73 expression • ENTPD1 expression
|
Imfinzi (durvalumab) • gemcitabine • oleclumab (MEDI9447) • IPH5201
Share via
